Adaptive Biotechnologies (ADPT) EBITDA Margin (2018 - 2026)

Adaptive Biotechnologies has disclosed EBITDA Margin across 9 years of filings, most recently posting 14.62% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 14.62%, up 296.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.87% (up 1002.0% YoY), and the FY2025 annual result was 5.48%, up 1913.0% from the prior year.
• EBITDA Margin came in at 14.62% for Q1 2026 at Adaptive Biotechnologies, down from 2.47% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 25.23% in Q3 2025 to a low of 322.32% in Q2 2023.
• The 5-year median for EBITDA Margin is 26.14% (2024), against an average of 63.15%.
• Across the five-year window, EBITDA Margin plunged 20207 bps in 2023 and soared 29619 bps in 2024, its largest moves.
• Adaptive Biotechnologies' EBITDA Margin stood at 70.99% in 2022, then soared by 69 bps to 21.75% in 2023, then soared by 199 bps to 21.61% in 2024, then plunged by 111 bps to 2.47% in 2025, then plunged by 493 bps to 14.62% in 2026.
• The last three EBITDA Margin figures came in at 14.62% (Q1 2026), 2.47% (Q4 2025), and 25.23% (Q3 2025), per Business Quant data.